Male medicine has a bad reputation in India and, indeed, in the world.
It is considered to be unprofessional, unprofessional and unprofessionalistic, particularly among the younger generation.
This is partly because of the way it is presented to the public, and partly because it is seen as a male preserve, not to mention its poor quality.
It has even led to an epidemic of female physicians and a growing number of women doctors in the profession.
However, as we get to the age of men, and we are starting to see more women in medicine, we need more of them in it, Dr BudDha Malalai, a clinical professor at the Indian Institute of Medical Sciences, said in an interview with NDTV.
“It is not just about gender, it is about what kind of medicine is good for our society and the way we should think about health.”
Dr Malalani is also a pioneer in the field of prostate cancer treatment, which was developed in collaboration with the American University of Pennsylvania.
His groundbreaking research has helped to lower the incidence of prostate-specific antigen, the prostate-related genetic abnormality that causes the disease, and to find new therapies for men with the disease.
“A lot of my colleagues are starting from the premise that prostate cancer is not cancer, but a very treatable disease, something that you can live with for life,” Dr Malala said.
“The reason I started doing this is because there are no cure for prostate cancer, there is no treatment for it.
It was a question of how to treat the disease without harming the patient, without making them sick, without destroying their quality of life.”
“It was a very difficult thing to find out if there is a cure, and it was very difficult to find a way to make it safe for a patient,” Dr Mandel said.
Dr Mala says the key to finding a cure is not the standard treatment, but finding a drug that can reverse the symptoms.
The drug can be a compound called pembrolizumab, which has shown some success in trials in people with advanced prostate cancer.
The idea is that the drug will slow down the disease and reduce the growth of prostate tumors.
Dr Mandela said the pharmaceutical company Eli Lilly and Co has developed a drug called povidone-emtricitabine, or PME, that has shown promising results in trials with patients with advanced cancer.
Dr Makhlum-Tazir has used the same approach to treat prostate cancer patients, and Dr Mandeli said he had been using it for more than a decade.
“He is the one who is in charge of finding a vaccine, which means we have to start by making sure it is safe and effective, which is very important,” Dr Mascarell said.
While there are few trials to date to prove the efficacy of PME for treating prostate cancer in humans, it has shown promise in animal models, Dr Masyamadi said.
Povidones are a class of drugs developed by the US biotech firm AstraZeneca.
The company sells the drug as povalidone, and there are currently about 400,000 doses of it in India.
PME is not an approved drug for prostate cancers, but Dr Mabile said it could potentially be used to treat other types of cancers, including ovarian and lung cancer.
“We need to do a lot of studies, but we are looking into it,” Dr Muhaisa said.
A key question that needs to be answered is whether the drug would also be effective against cancers of the prostate or any other parts of the body.
Dr Mahbubuddin Siddiqui, an assistant professor at Johns Hopkins University School of Medicine and director of the Johns Hopkins Global Program on Pregnancy and Breastfeeding, said PME could potentially provide relief to men and women suffering from the disease of the testicles.
“There are very few men in India who are able to get pregnant with boys, and in the absence of men getting their testicles removed, they can’t have their sons, so it is very difficult for them to get their testicular function restored,” Dr Siddiquia said.
Male doctors are more likely to prescribe povids to men with cancer, because there is less risk of side effects.
“But it is important to recognise that there is an increased risk of harm, and this risk is greater in men, not women,” Dr Mahibali said.
The treatment is also not cheap.
The price tag for a single dose of PMEs in India is around $300, according to Dr Mahabir.
A single dose can cost $25,000 to $60,000.
Dr Mundi, the clinical professor, said that there was also a risk that women who are pregnant with a boy might not be able to have children